Pay in 4 interest-free payments of $7.07 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Dont miss Food Navigators broadcast series on Weight Management Join industry leaders and scientists on November 13 & 19 as we explore how the rise of GLP-1 weight-loss drugs is disrupting the food & beverage space and uncover how functional foods, bioactive ingredients and next-gen formulations can reshape satiety, metabolism and brand opportunity
doi:10.1002/dta.2152
Bottom Line Here's what the data tells us: GI side effects dominate: nausea, diarrhea, vomiting, constipation Higher efficacy = slightly higher side effects at maximum doses Glucagon adds benefits: liver fat reduction, increased energy expenditure Slow escalation helps: 20+ week titration minimizes symptoms Still investigational: Phase 3 trials ongoing, FDA decision expected 2025-2026 Sources Retatrutide Phase 2 Trial (Jastreboff et al., NEJM 2023) TRIUMPH Phase 3 Trial (ClinicalTrials.gov) ClinicalTrials.gov Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice
Individuals at risk of AD or with diabetes may be in the early or middle biological stage of AD, offering a greater opportunity for GLP-1RAs to provide neuroprotection
The absence of direct trials does not mean the combination is risky or ineffective
US$ 22.37
US$ 24.32
US$ 23.99
US$ 27.02
US$ 27.37
